1. Scrip
  2. >>Business
  3. >>Strategy

AMR Roundtable Part 1: Incentives Spur Antimicrobial Investments, But More Needed

 
• By Mandy Jackson

Scrip spoke with the CEOs of antibiotic firm Zavante and antifungal specialist Amplyx as well as a BARDA official who oversees antibiotic funding programs during a roundtable discussion at BIO about what's needed to boost antimicrobial drug development. Topics addressed in this part 1 of the discussion include company funding strategies, impact of the CARB-X program, and unique opportunities and challenges for antifungals.

Antibiotic resistant bacteria closeup biofilm

The world needs more antibiotics and antifungal medicines to combat antimicrobial resistance (AMR), but without a big return on investment, drug makers need incentives to develop and commercialize new anti-infectives – and if the market won't provide them, the government may have to step in.

Scrip moderated a roundtable discussion about government incentives that are needed to boost private investment that will push new therapies into development and pull profits out of new antimicrobial treatments during the BIO International Convention last month in San Diego. BIO subsequently posted a

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Strategy

Affimed’s ASCO ‘Hail Mary’ As Survival Chances Slim

 
• By Kevin Grogan

The German biotech has been forced into insolvency and NASDAQ suspension.

Mission Vision: How Roche Hopes To Impact Eye Health Outcomes In APAC

 
• By Anju Ghangurde

Roche Pharmaceuticals’ area head, Asia Pacific, outlines how the Swiss group is helping nurture the wider ecosystem and setting itself up for a bigger play in the ophthalmology space by combining scientific expertise with regional insights.

Apnimed’s AD109 Could Be A Wake-Up Call For Sleep Apnea Market

 
• By Joseph Haas

The first of two Phase III trials in obstructive sleep apnea showed Apnimed’s combination pill can offer a therapeutic alternative to entrenched CPAP devices.

First Blood-Based Test Cleared For Alzheimer’s Boosts Anti-Amyloid Drugs

 
• By Mandy Jackson

The US FDA approval of Fujirebio’s Lumipulse should boost access to medicines like Eisai’s Leqembi and Lilly’s Kisunla; the firms are praising patients’ access to earlier diagnoses.

More from Business

First Blood-Based Test Cleared For Alzheimer’s Boosts Anti-Amyloid Drugs

 
• By Mandy Jackson

The US FDA approval of Fujirebio’s Lumipulse should boost access to medicines like Eisai’s Leqembi and Lilly’s Kisunla; the firms are praising patients’ access to earlier diagnoses.

Regeneron Sees 23andMe Buy As Complement To Genetics Platform

 
• By Alaric DeArment

The consumer genomics firm will operate as a subsidiary, while Regeneron plans to leverage its database for drug discovery and trial design efforts.

How Much Does Biopharma Contribute To The US Economy?

 
• By Jessica Merrill

A new IQVIA report highlights how the sector benefits the US through metrics like the economy, employment and health.